Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06238726
Other study ID # 2023-1504
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 25, 2024
Est. completion date May 13, 2025

Study information

Verified date June 2024
Source Geisinger Clinic
Contact Amir Goren, PhD
Phone 570-214-3495
Email agoren@geisinger.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test whether messages encouraging patients to ask about a Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates. The study will also test which of several message versions is most effective.


Description:

Shingles is a painful disease caused by reactivation of the varicella zoster (chickenpox) virus. About a third of adults in the US will develop shingles in their lifetime, with the highest prevalence in adults ages 50 and older. Roughly one in ten patients with shingles develops complications that can lead to long-term pain and inflammation). Shingrix, a two-shot vaccine series, is highly effective at preventing shingles and is recommended by the CDC for all adults ages 50 and over. The present study will test whether sending patients messages encouraging them to ask about Shingrix at an upcoming primary care appointment increases vaccination rate relative to Passive Control (no messages). Additionally, four message arms will vary as a function of risk (message includes or does not include a statement telling patient they are at high risk for shingles because they are age 50+) and facts (message includes or does not include several facts about shingles and Shingrix), with the no-high-risk, no-facts arm designated as the Active Control arm. Message arms will be crossed with two additional randomized variables: number of messages (2 messages or 3 messages) and cost information (the presence or absence of information about the cost of Shingrix in the final message). Enrollment timing will vary by insurance group. Enrollment will begin with patients who have a Geisinger Health Plan (GHP) membership that allows them to get Shingrix at no cost (this includes the vast majority of GHP members), because existing data allow the study team to easily identify these patients and inform them about their Shingrix coverage in cost messages. Enrollment for patients who are not GHP members (and the few patients with a GHP plan that is not Shingrix eligible) will begin following the development of an automated internal process that will allow cost messages to include information about patients' individualized Shingrix insurance benefits. Alternatively, if development is delayed approximately 2 months or longer from the launch of enrollment for GHP members, the study team may decide in collaboration with Geisinger leadership to begin enrolling patients without GHP using a generic cost message (e.g., "Most patients can get Shingrix at no cost"). Enrollment for each insurance group (GHP members, non-GHP members) will begin with a 2-week pilot period, with a limited number of new patients (e.g., 100 to 200) enrolled per day in that insurance group (these patients will be randomly selected from the eligible patients). During the pilot period, the study team will communicate frequently with clinical partners to ensure there are no issues before full rollout. If issues arise, the pilot period may be extended. If the pilot period does not result in any changes to outreach, or involves only trivial changes, patients enrolled in the pilot period will be included in analysis. If there are more substantive changes to the outreach following the pilot period, patients enrolled during that period will be excluded from analysis. Once full rollout occurs, enrollment for each insurance group will last for 1 year. Study enrollment will be complete 1 year following full rollout for non-GHP members. Anticipated enrollment is at least 50,000. UPDATE ON 4/15/24: Following a recent review of clinical operational workflows, clinical stakeholders determined that the copays estimated through the automated process will typically not be applicable to non-GHP members. Therefore, in the coming weeks, text messaging to eligible non-GHP members will begin, with a generic cost message for those randomized to be sent a cost message.


Recruitment information / eligibility

Status Recruiting
Enrollment 50000
Est. completion date May 13, 2025
Est. primary completion date May 13, 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Age 50+ - Has not received any doses of the Shingrix vaccine according to the Geisinger EHR - Has a non-acute in-person Geisinger primary care appointment in a department that stocks Shingrix scheduled with enough time to be randomized Exclusion Criteria: - Cannot be contacted via the communication modality being used in the study (e.g., patient portal, SMS), e.g., due to insufficient/missing contact information in the EHR or because they opted out - Patient does not have an approved insurance on file for Shingrix outreach for their appointment type or department - Appointment type or department not approved for outreach by Geisinger leadership at the time of outreach

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reminder
Shingrix messages via SMS, patient portal, email, and/or another modality

Locations

Country Name City State
United States Geisinger Clinic Danville Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Geisinger Clinic Massachusetts Institute of Technology, National Bureau of Economic Research, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other First Shingrix vaccination Received a first Shingrix vaccination in the 10 days following enrollment (y/n) In the 10 days following enrollment
Other Attended scheduled appointment Attended the target Shingrix-eligible appointment (y/n) 3 days after enrollment
Other First Shingrix vaccination Received a first Shingrix vaccination in the 14 months following enrollment (y/n) In the 14 months following enrollment
Other Time to first Shingrix vaccination Number of days between enrollment and first Shingrix vaccination In the 14 months following enrollment
Other Completion of Shingrix series Completed Shingrix vaccination series by getting a second Shingrix vaccination (y/n) In the 14 months following enrollment
Other Time to completion of Shingrix series Number of days between first and second Shingrix vaccination In the 14 months following enrollment
Other Shingles diagnosis Diagnosed with shingles (y/n) In the 14 months following enrollment
Primary First Shingrix vaccination Received a first Shingrix vaccination on the appointment date (y/n) 3 days after enrollment
See also
  Status Clinical Trial Phase
Completed NCT03305731 - Activating Behavior for Lasting Engagement After Stroke N/A
Completed NCT04035395 - Salud y Vida 2.0: Enhancing Integrated Behavioral Health for Diabetics in the Rio Grande Valley N/A
Active, not recruiting NCT06089876 - The Use of Mobile Applications in Obese and Overweight Adolescents for Health Improvement N/A
Active, not recruiting NCT06057727 - Behavioral Economics to Improve Flu Vaccination Using EHR Nudges N/A
Not yet recruiting NCT04096404 - Gene-based Personalised Diet and Physical Activity Advice on Adiposity Indices Personalised Diet and Physical Activity Advice on Adiposity Indices in University Students N/A
Completed NCT05100524 - Motivational Interview for Daily Living Activities in Elderly People Undergoing Total Knee Replacement N/A
Recruiting NCT06394882 - FamCe-HLP- Family-centered Obesity Management Program in Primary Care Settings N/A
Not yet recruiting NCT04961983 - A Comprehensive Travel Health Education for Tour Guides in Bali, Indonesia N/A
Enrolling by invitation NCT06408844 - Examining the Impact of Behavior Change Intervention N/A
Completed NCT04809519 - Integrative Nursing Based Multimodal Interventions for Uncontrolled Hypertensives N/A
Suspended NCT04113213 - Primary Care - Prescribing Lifestyle Adjustments for Cardiovascular Health N/A
Completed NCT04042467 - Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention N/A
Active, not recruiting NCT04641689 - Stand Up Kansas: An Intervention to Reduce Sedentary Behavior in the Home Work Environment N/A
Recruiting NCT06050850 - A Healthy Weight Intervention for Family Stress During the Early Phases of ALL Treatment: NOURISH-ALL
Withdrawn NCT04467034 - Evaluation of The Stanford Tobacco Prevention Toolkit N/A
Completed NCT03315286 - Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure N/A
Completed NCT04522245 - Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention N/A
Active, not recruiting NCT04633070 - Systematic Review of Health App Gamification for Lifestyle Intervention Adherence
Completed NCT03961061 - Increased Monitoring of Physical Activity and Calories With Technology N/A
Active, not recruiting NCT03734055 - Peer Approaches to Lupus Self-management N/A